Keyword: AMAG Pharmaceuticals

Already under shareholder pressure, AMAG faces an uncertain future after an advisory panel recommended the FDA pull Makena from the U.S. market.

Locked in a proxy tussle with activist investor Velan Capital, Progenics opted to sell out rather than negotiate. But Velan isn't giving up the fight.

Amid a proxy fight with an activist investor, AMAG implored shareholders to hold the line on its leadership. Turns out the plan has changed.

AMAG wants to spurn an activist investor’s attempt to take board seats. With a drug prospect’s approval on the line, will the call for change grow?

Activist investor Caligan wants to rework the board of AMAG, the maker of female libido med Vyleesi, but the company isn’t giving up yet.

AMAG's female libido drug Vyleesi has just won FDA approval. But will it reach blockbuster state? Management and analysts have different opinions.

When looking for consumer marketing lessons that can translate to pharma, Amag Pharmaceutical needed to look no further than its own operations.

Industry lobbying group PhRMA has cleared its decks of nearly two dozen members as it tries to distance itself from those companies most likely to catch heat over drug pricing practices.

AMAG Pharmaceuticals has big ambitions for its women’s health business, so it’s snapped up the rights to a new med, Intrarosa, to beef up that portfolio. And it’s bringing on 150 new reps to detail the med.

Drugmaker AMAG Pharmaceuticals said it reached key development milestones for two of its pipeline drugs: the subcutaneous autoinjector version of Makena and the anemia drug Feraheme.